Sequence- and structure-specific RNA oligonucleotide binding attenuates heterogeneous nuclear ribonucleoprotein A1 dysfunction

• Published in: Frontiers in molecular biosciences Vol. 10; p. 1178439
• Main Authors: Clarke, Joseph P, Thibault, Patricia A, Fatima, Sakina, Salapa, Hannah E, Kalyaanamoorthy, Subha, Ganesan, Aravindhan, Levin, Michael C
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.06.2023
• Subjects: hnRNPA1; Molecular Biosciences; optogenetics; RNA oligonucleotide; RNA-protein interaction; stress granules; stress granules; hnRNPA1; RNA-protein interaction; RNA oligonucleotide; optogenetics
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2023.1178439

The RNA binding protein heterogeneous nuclear ribonucleoprotein A1 (A1) regulates RNA metabolism, which is crucial to maintaining cellular homeostasis. A1 dysfunction mechanistically contributes to reduced cell viability and loss, but molecular mechanisms of how A1 dysfunction affects cell viability and loss, and methodologies to attenuate its dysfunction, are lacking. Utilizing molecular modeling and an optogenetic system, this study examined the consequences of RNA oligonucleotide (RNAO) treatment on attenuating A1 dysfunction and its downstream cellular effects. and thermal shift experiments revealed that binding of RNAOs to the RNA Recognition Motif 1 of A1 is stabilized by sequence- and structure-specific RNAO-A1 interactions. Using optogenetics to model A1 cellular dysfunction, we show that sequence- and structure-specific RNAOs significantly attenuated abnormal cytoplasmic A1 self-association kinetics and A1 cytoplasmic clustering. Downstream of A1 dysfunction, we demonstrate that A1 clustering affects the formation of stress granules, activates cell stress, and inhibits protein translation. With RNAO treatment, we show that stress granule formation is attenuated, cell stress is inhibited, and protein translation is restored. This study provides evidence that sequence- and structure-specific RNAO treatment attenuates A1 dysfunction and its downstream effects, thus allowing for the development of A1-specific therapies that attenuate A1 dysfunction and restore cellular homeostasis.